Discovery and Structure−Activity Relationship of (1R)-8-Chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a Selective Serotonin 5-HT_2C Receptor Agonist for the Treatment of Obesity

Citations Over TimeTop 10% of 2007 papers

Abstract

The synthesis and SAR of a novel 3-benzazepine series of 5-HT2C agonists is described. Compound 7d (lorcaserin, APD356) was identified as one of the more potent and selective compounds in vitro (pEC50 values in functional assays measuring [(3)H]phosphoinositol turnover: 5-HT2C = 8.1; 5-HT2A = 6.8; 5-HT2B = 6.1) and was potent in an acute in vivo rat food intake model upon oral administration (ED50 at 6 h = 18 mg/kg). Lorcaserin was further characterized in a single-dose pharmacokinetic study in rat (t1/2 = 3.7 h; F = 86%) and a 28-day model of weight gain in growing Sprague-Dawley rat (8.5% decrease in weight gain observed at 36 mg/kg b.i.d.). Lorcaserin was selected for further evaluation in clinical trials for the treatment of obesity.

Related Papers

• → Synthesis and Characterization of Photolabile Derivatives of Serotonin for Chemical Kinetic Investigations of the Serotonin 5-HT₃ Receptor(2000)58 cited
• → Characterization of 5‐HT_1A,B and 5‐HT_2A,C Serotonin Receptor Binding(2001)5 cited
• → Evidence for serotonin (5HT) binding sites on murine lymphocytes(1987)21 cited
• Re-evaluation of the uptake of desoxyfructo-serotonin by human platelets, and of its effect on the uptake of serotonin.(1979)
• → Serotonin (5-HT)-induced enhancement in the colonic motility is mediated through 5-HT1-like and 5-HT2 receptors in dogs(1995)